Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The characteristic laboratory findings of non-responsiveness to intravenous immunoglobulin in children with Kawasaki disease

가와사끼병 재 치료군의 특징적인 검사 지표

  • Cho, Han Gil (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hospital) ;
  • Cho, Young Kuk (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hospital) ;
  • Ma, Jae Sook (Department of Pediatrics, Chonnam National University Medical School Chonnam National University Hospital)
  • 조한길 (전남대학교 의과대학 전남대학교병원 소아청소년과) ;
  • 조영국 (전남대학교 의과대학 전남대학교병원 소아청소년과) ;
  • 마재숙 (전남대학교 의과대학 전남대학교병원 소아청소년과)
  • Received : 2009.09.03
  • Accepted : 2009.10.27
  • Published : 2010.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Although intravenous immunoglobulin (IVIG) treatment is an effective first-line treatment for Kawasaki disease, 10-20% of the patients develop persistent fever or coronary artery complications. Medical records of Kawasaki disease patients were reviewed to assess the characteristic laboratory findings of IVIG nonresponsiveness. Methods : We reviewed the clinical records of 118 children with Kawasaki disease who were treated at the Chonnam National University Hospital from March 2003 to February 2008. The laboratory findings of the IVIG-responder group (n=110) and the IVIG-nonresponder group (n=8) were compared at admission day and at 48 hours and 14 days after IVIG administration. Results : At admission, the level of creatine kinase (CK) was lower (P =0.03) and that of total protein was higher (P <0.01) in the nonresponders than in the responders. At 48 hours after IVIG administration, the white blood cell (WBC) count (P =0.04) and neutrophil% (P <0.01) was higher in the nonresponders than in the responders. The neutrophil% (P <0.01) and CK (P =0.01) level at admission was lower than that at 48 hours after IVIG administration in the responders; this decrease was not as apparent in the nonresponders. Conclusion : IVIG nonresponders have lower CK and higher total protein levels at admission and higher WBC count and neutrophil% at 48 hours after IVIG administration. The decrease in the neutrophil% and CK level between at admission and at 48 hours after IVIG administration is remarkably higher in responders than in nonresponders.

목 적 : 가와사끼병에서 1차 치료로 고용량 정맥용 면역글로불린(IVIG)의 사용이 가장 효과적인 것으로 알려져 있으나 이 중 약 10-20% 정도는 반응을 보이지 않아 발열이 지속되어 관상동맥의 합병증의 위험이 높아진다고 알려져 있다. 1차 치료에 반응하지 않은 가와사끼병 환자를 조기에 찾기 위한 검사실 지표에 대한 연구가 있으나 일관된 결과를 보이지 않고 있다. 본 연구에서는 IVIG 재 투여를 받은 재 치료군의 임상소견과 검사실 지표분석을 통해 재 치료군의 특징적인 검사 소견을 찾아 보고자 한다. 방 법 : 2003년 3월부터 2008년 2월까지 만 5년간 전남대학교병원 소아청소년과에서 입원하여 치료받았던 가와사끼병 환아 118명을 대상으로 후향적으로 조사하였고 IVIG에 반응을 보인 군(반응군, responder group, n=110)과 IVIG 1회 투여로 반응을 보이지 않아 재 치료 한 군(재 치료군, nonresponder group, n=8)을 비교 평가하였다. 정맥용 면역글로불린(2.0 g/kg) 투여전, 투여 48시간 후, 투여 14일 후의 백혈구 수, 혈색소 수치, 혈소판 수치, ESR, CRP, 총 단백, 알부민, AST, ALT, lactate dehydronase (LDH), BUN, creatinine, creatine kinase (CK), CK-MB 등의 검사실 지표와 나이, 성별, 발열에서 IVIG 투여하기까지 기간 등을 비교 측정하였다. 결 과 : 초기치료에 반응하지 않아 재 치료 한 경우는 118례 중 8례(6.8%) 였다. 이 군에서 IVIG 투여 전 낮은 CK (P =0.03), 높은 총 단백 수치(P <0.01)를 보였고 IVIG 투여 2일 후 높은 백혈구 수치(P =0.04), 중성구 분획(P <0.01)이 통계학적으로 의미 있는 결과로 나타났다. 또한 중성구 분획(P <0.01)과 CK (P =0.01)의 경우 IVIG 투여 전 비해 투여 2일 후 반응군에서 재 치료군보다 큰 폭의 감소를 보였다. 결 론 : 가와사끼병 환아 중 IVIG 투여 전 낮은 CK, 높은 총단백 수치와 IVIG 투여 48시간 후 높은 백혈구 수치, 높은 중성구 분획 보인 환아에서 재 치료 가능성이 높았고, 재 치료군에 비해 반응군에서 CK 등의 감소폭이 큰 점이 특징적이었으며 이의 관련성에 대한 향후 추가적인 연구가 필요할 것으로 생각된다.

Keywords

Acknowledgement

Supported by : Chonnam National University Hospital Research Institute of Clinical Medicine

References

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16:178-222
  2. Newburger JW, Burns JC. Kawasaki syndrome. Cardiol Clin 1989;7:453-65
  3. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978;61:100-7
  4. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et. al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-8
  5. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. Treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7 https://doi.org/10.1056/NEJM198608073150601
  6. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:e78 https://doi.org/10.1542/peds.105.6.e78
  7. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8 https://doi.org/10.1007/s00246-002-0216-2
  8. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr 2000;137:177-80 https://doi.org/10.1067/mpd.2000.107890
  9. Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med 1995;162:322-7
  10. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matumoto Y, et al. Prediction of non-response to intravenous high-dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6 https://doi.org/10.1067/mpd.2000.104815
  11. Inoue Y, Kobavashi T, Tomomasa T, Morikawa A. Macro creatine kinase in Kawasaki disease. Pediatr Cardiol 1999;20:206-7 https://doi.org/10.1007/s002469900442
  12. Yun SW. Diagnostic value of serum cardiac Troponin T, Troponin I and CK-MB in acute Kawasaki disease. Korean Circ J 2009;34:582-92
  13. Engle MA, Fatica NS, Bussel JB, O'Loughlin JE, Snyder MS, Lesser ML. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Preliminary reort. Am J Dis Child 1989;143:1300-4
  14. Ahn SY, Hong SY, Kim NS, Lee HB, Moon SJ, Lee H. Comparison between treatment with aspirin alone and the combined treatment with aspirin with gammaglobulin in Kawasaki disease. J Korean Pediatr Soc 1990;33:1380-7
  15. Leem BY, Chung CS, Cha SH, Choi YM, Ahn CI. A comparative study of therapeutic effect of intravenous gammaglobulin plus aspirin versus aspirin alone in Kawasaki syndrome. J Korean Pediatr Soc 1989;32:1408-14
  16. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9 https://doi.org/10.1016/S0022-3476(96)70447-X
  17. Kim NY, Chang CH, Lee DS, Kim DK, Choi SM, Kim WT. A clinical study of intravenous gammaglobulin retreatment in Kawasaki disease. J Korean Pediatr Soc 2000;43:223-8
  18. Hong DE, Lee KY, Han JW, Hwang SS, Lee KS. Treatment of intravenous immune-globulin resistant Kawasaki disease with corticosteroids. J Korean Pediatr Soc 1997;40:1453-7
  19. Kil HR. Recent advances in clinical field of Kawasaki disease. J Korean Pediatr Cardiol 2002;6:75-80
  20. Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 2006;95:189-93 https://doi.org/10.1080/08035250500327328
  21. Ogino H, Ogawa M, Harima Y, Kono S, Ohkuni H, Nishida M, et al. Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease. Prog Clin Biol Res 1987;250:555-6
  22. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44 https://doi.org/10.1016/S0140-6736(04)16814-1
  23. Shim SY, Heo MY, Kim HS, Sonh S. High-dose intravenous immmune globulin retreatment in Kawasaki disease. J Korean Pediatr Soc 2002;45:1273-7
  24. Cho EY, Lee MH, Kang KS, No ES, Lee DJ, Choi MB, et al. Serum C-Reactive Protein as a predictor for cardiac sequelae in Kawasaki disease. J Korean Pediatr Cardiol 2002;6:90-5
  25. De Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998;133:254-8 https://doi.org/10.1016/S0022-3476(98)70229-X